Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Imugene ( (AU:IMU) ) has issued an update.
Imugene Limited has issued 68,236,857 fully paid ordinary shares at $0.33 per share as part of a placement announced earlier. This issuance is part of their strategic efforts to fund ongoing research and development in their immunotherapy pipeline, positioning the company to advance its clinical and commercial milestones in the rapidly growing global cancer treatment market.
The most recent analyst rating on (AU:IMU) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.
More about Imugene
Imugene is a clinical stage immuno-oncology company focused on developing innovative immunotherapies to activate the immune system of cancer patients. Their product pipeline includes an allogeneic cell therapy CAR T drug targeting blood cancer, multiple B-cell vaccine candidates, and an oncolytic virotherapy aimed at treating various cancers. Imugene is supported by a team of international cancer experts and aims to transform cancer treatment globally.
Average Trading Volume: 688,967
Technical Sentiment Signal: Sell
Current Market Cap: A$70.31M
Learn more about IMU stock on TipRanks’ Stock Analysis page.